Endo International PLC's decision to withdraw the long-acting opioid Opana ER (oxymorphone extended-release) from the US market avoids a big fight with FDA over a product that represented little in the way of sales.
On July 6, Endo said it would voluntarily withdraw the current Opana ER formulation from the market pursuant to an...




